Mismatch Repair-Deficient Tumor Management
- What: The FDA approved arexvy, a respiratory syncytial virus (RSV) vaccine, for adults aged 60 years and older.
- When: May 3, 2023, with updated recommendations in September 2025.
- Why it Matters: RSV causes notable illness and hospitalization in older adults, and this is the first widely available vaccine to prevent it.
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and Why It’s a threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Though, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Before the availability of a vaccine,RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the United States. The virus weakens the respiratory system, making individuals more vulnerable to secondary infections and exacerbating existing conditions like chronic obstructive pulmonary disease (COPD) and heart failure.
the impact of RSV isn’t just about immediate illness. recovery can be prolonged, leading to a decline in functional status and reduced quality of life. This is particularly concerning for seniors who may already be managing multiple health challenges.
The Arexvy Vaccine: How It Works
Arexvy, developed by GSK, is a recombinant subunit vaccine. This means it doesn’t use a live virus. Rather, it contains a stabilized prefusion F protein, a key component of the RSV virus that triggers an immune response. The vaccine works by teaching the body to recognize and fight off the RSV virus if exposed. Clinical trials have demonstrated its effectiveness in preventing RSV-associated lower respiratory tract disease (LRTD).
The pivotal clinical trial, published in the New England Journal of Medicine on September 25, 2025, involved over 12,600 adults aged 60 years and older. Results showed that Arexvy had an overall vaccine efficacy of 82.6% against RSV-associated LRTD with at least one symptom. Efficacy was also observed against severe LRTD, with a 94.1% reduction in cases requiring hospitalization.
Key findings from the Clinical Trials (September 2025)
| Outcome | Arexvy Group | Placebo Group | Vaccine Efficacy (%) |
|---|---|---|---|
| RSV-associated LRTD (≥1 symptom) | 1.4% | 8.0% | 82.6 |
| Severe RSV-Associated LRTD (Hospitalization) | 0.4% | 0.7% | 94.1 |
| RSV-Associated LRTD with 3+ symptoms | 0.8% | 4.0% | 80.0 |
Who Should Get the RSV Vaccine?
The Centers for Disease Control and prevention (CDC) recommends that adults aged 60 years and older may receive a single dose of RSV vaccine, based on shared clinical decision-making with their healthcare provider. This means a discussion about individual risk factors, potential benefits, and preferences is crucial. Factors to consider include age, underlying health conditions, lifestyle, and overall health status.
It’s important to note